Small Sample, Big Stakes: Why Handling Matters in Pancreatic Cancer
When someone is diagnosed with pancreatic cancer, a small piece of tissue, often no bigger than a few grains of rice, becomes one of the most important objects in their entire care journey. That tiny sample is where the diagnosis is confirmed. It's also where doctors look for the clues that can guide treatment, open the door to clinical trials, and fuel the research that will help the next patient.
A new position statement from the Associazione Italiana Studio Pancreas (AISP) and I-PCC, published in Digestive and Liver Disease, focuses on something that rarely makes headlines but quietly affects everyone with this disease: how those precious samples are collected, handled, and stored. It may sound like a technical detail. In reality, it can determine whether a patient's tissue yields the answers their doctors are searching for.
Why pancreatic cancer makes this so hard
Pancreatic cancer is uniquely difficult to sample. Tumors are often small, hard to reach, and surrounded by a dense, fibrous tissue that can make up most of what's removed, leaving very few actual cancer cells to work with. Many patients are diagnosed when the disease has already spread, so samples sometimes come from other sites, like the liver. And frequently, a single needle biopsy is the only opportunity to obtain material that can inform treatment. In other words, there is very little tissue, and enormous pressure on every piece of it to deliver.
The first minutes and hours matter more than you'd think
Here's something that surprises many people: a tissue sample begins to change the moment it leaves the body. The time between removal and preservation (what specialists call "cold ischaemia) is a window in which delicate molecules can start to break down. Even a delay of a few hours, or storage at the wrong temperature, can quietly erode the information a sample carries, including the markers doctors rely on to choose therapies.
That's why the AISP experts emphasize speed and consistency: getting samples preserved promptly, keeping them cool when processing is delayed, and carefully controlling how they're "fixed" (the chemical step that stabilizes tissue for the lab). Done well, these steps protect the sample. Done inconsistently, as still happens across different hospitals, they can compromise it before a single test is even run.
Preserving the future, not just the present
Traditionally, tissue is preserved in wax blocks that can sit on a shelf for years, excellent for routine diagnosis. But the most advanced tests, from detailed genetic sequencing to growing patient-derived "mini-tumors" (organoids) in the lab, often work best on tissue that has been frozen fresh, quickly, and stored properly in a biobank.
This is why the paper encourages, whenever possible, setting aside and freezing a portion of fresh tumour tissue for the future. Therapies and tests that don't exist today may become available during a patient's disease course. A well-preserved sample keeps those doors open.
One sample, many jobs and a clear order of priorities
Modern pancreatic cancer care asks a lot of a single specimen: confirm the diagnosis, identify treatable mutations, potentially match a patient to a trial, and support research. When tissue is scarce, these needs can compete. The AISP offers a clear, patient-first principle. Diagnosis always comes first. Then come the biomarkers that could directly change a patient's treatment. Only after those needs are met should tissue be reserved for research and biobanking. Importantly, the authors stress that patient care and research are not rivals, many of the biomarkers used in clinics today exist precisely because earlier patients' samples were carefully collected and studied.
Why standardization is really about fairness
Perhaps the most important message for patients is this: a sample taken in one hospital should be handled to the same high standard as a sample taken anywhere else. Today, that isn't always the case. By setting shared, practical standards, this document aims to make sure that a patient's access to precision diagnosis, clinical trials, and future therapies doesn't depend on which centre they happen to walk into.
“Every conversation we have about the value of tissue, every effort to support biobanking and research, helps ensure that no patient's sample, and no patient's chance, is lost to something as preventable as a handling delay”.